E

Editas Medicine
D

EDIT

1.22000
USD
-0.03
(-2.40%)
مغلق
حجم التداول
38,945
الربح لكل سهم
-3
العائد الربحي
-
P/E
-0
حجم السوق
100,708,681
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ALNY
    ALNY
    -2.740
    (-1.10%)
    246.360 USD
    B
    BEAM
    0.030
    (0.13%)
    23.440 USD
    B
    BLUE
    0.05000
    (0.60%)
    8.35000 USD
    C
    CRSP
    0.260
    (0.65%)
    40.520 USD
    N
    NTLA
    0.09000
    (0.96%)
    9.50000 USD
    R
    RGEN
    -2.255
    (-1.38%)
    160.600 USD
    S
    SGMO
    -0.00500
    (-0.45%)
    1.10000 USD
    TMO
    TMO
    -1.98
    (-0.35%)
    559.67 USD
    VRTX
    VRTX
    4.97
    (1.19%)
    422.10 USD
    المزيد
الأخبار
المقالات

العنوان: Editas Medicine

القطاع: Healthcare
الصناعة: Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.